Table 3.
Treatment regimens analysed among the eligible studies
| Treatment regimens | Treatment regimen subgroups |
|---|---|
| Containing PIB | PIB + GLE |
| PIB + GLE + RBV | |
| PIB + PTV/r + RBV | |
| Containing DCV | DCV + SOF |
| DCV + SOF + RBV | |
| Containing GZR | GZR + RZR + MK-3682 |
| GZR + EBR + MK-3682 | |
| GZR/EBR + SOF | |
| Containing Peg-IFN | Peg-IFN + RBV |
| Peg-IFN + SOF + RBV | |
| Containing LDV | LDV + SOF |
| LDV + SOF + RBV | |
| Containing OBV | OBV + PTV/r |
| OBV + PTV/r + RBV | |
| OBV + PTV/r + SOF | |
| OBV + PTV/r + SOF + RBV | |
| Containing SOF | SOF + RBV |
| Containing VEL | VEL100 + SOF |
| VEL100 + SOF + VOX | |
| VEL100 + SOF + RBV |
DCV daclatasvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, LDV ledipasvir, OBV ombitasvir, Peg-IFN pegylated interferon, PIB pibrentasvir, PTV paritaprevir, RBV ribavirin, r ritonavir, SOF sofosbuvir, RZR ruzasvir, VEL100 velpatasvir 100 mg, VOX voxilaprevir